Abstract: This invention relates to the use of a CYP2D6 inhibitor in combination with a drug having CYP2D6 catalyzed metabolism, wherein the drug and the CYP2D6 inhibitor are not the same compound; and pharmaceutical compositions for said use.
Abstract: This invention relates to combinations of an abl-, PDGF-Receptor-and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to &agr;1-acidic glycoprotein (AGP), as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to inhibition of abl-, PDGF-Receptor- and/or Kit-receptor tyrosine kinase. In particular, the invention relates to products or combinations comprising and abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase inhibitor with an organic compound capable of binding to AGP, either in fixed combination or for chronologically staggered or simultaneous administration, and the combined used of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, especially those that can be treated by inhibition of abl-, PDGF-Receptor- and/or Kit receptor-tyrosine kinase activity.
Type:
Application
Filed:
October 7, 2002
Publication date:
July 3, 2003
Inventors:
Carlo Gambacorti-Passerini, Philipp Lecoutre
Abstract: The invention provides a novel heterocyclic ring condensed benzothiazine compound which is effective for prevention or remedy of disease, in which histamine, leukotriene and the like participate. The heterocyclic ring condensed benzothiazine compound of the present invention or a pharmacologically acceptable salt thereof is effective for prevention or remedy of disease, in which a chemical mediator, such as histamine, leukotriene and the like, participate, for example, asthma, allergic coryza, atopic dermatitis, hives, hay fever, gastrointestinal allergy, food allergy and the like.
Abstract: An antidepressant or a pharmaceutically acceptable salt thereof, and an opiate antagonist or a pharmaceutically acceptable salt thereof, are used to treat refractory depression characterized by dissociation.
Abstract: The present invention relates to the use of a compound inhibiting the expression of the TPT1 gene, or of the products which it controls, for producing a drug which is intended for treating cancer.
Type:
Application
Filed:
November 27, 2002
Publication date:
May 8, 2003
Applicant:
Molecular Engines Laboratories
Inventors:
Adam Telerman, Robert Amson, Marius Tuijnder
Abstract: This invention relates to a compound of formula I:
or a pharmaceutically acceptable salt thereof;
in which preferably R3, R4 and R6 are each hydrogen;
X is C═O or CH2; and
R7 and R8 are each independently selected from the group consisting of hydrogen, (C1-C12)alkyl, (C3-C8)cycloalkyl and (C1-C12)alkyl (C6-C14)aryl; or
R7 and R8 when taken together form a (C2-C7)alkylene group; or
—NR7R8 together forms a (C2-C14)heterocyclic or substituted (C2-C14)heterocyclic. Such compounds modulate the activity of serine hydrolases and can be used in pharmaceutical compositions for the treatment of Alzheimer's disease.
Type:
Grant
Filed:
October 9, 2001
Date of Patent:
April 8, 2003
Assignee:
Dalhousie University
Inventors:
Sultan Darvesh, David Magee, Zdenek Valenta, Earl Martin
Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine, including promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more non-ionic surfactants and at least one amino acid and/or one polyol prior to administration to an animal such as a mammal.
Type:
Application
Filed:
June 26, 2002
Publication date:
February 13, 2003
Applicant:
Wyeth
Inventors:
Jianwei Yu, Pui-Ho Yuen, Virginia Paulate
Abstract: Compositions and methods are provided for reducing adverse reactions as a result of parenteral administration of certain phenothiazine derivatives such as promethazine hydrochloride. The active compound may be admixed with an effective amount of one or more cyclodextrin derivatives, and if desired, one or more non-ionic surfactants such as the partial esters of sorbitol and the polyoxyethylene oxides of long chain fatty acids such as the polysorbates.
Abstract: The present invention relates to the delivery of antipsychotics through an inhalation route. Specifically, it relates to aerosols containing antipsychotics that are used in inhalation therapy. In a composition aspect of the present invention, the aerosol comprises particles comprising at least 5 percent by weight of an antipsychotic. In a method aspect of the present invention, an antipsychotic is delivered to a mammal through an inhalation route. The method comprises: a) heating a composition, wherein the composition comprises at least 5 percent by weight of an antipsychotic, to form a vapor; and, b) allowing the vapor to cool, thereby forming a condensation aerosol comprising particles, which is inhaled by the mammal.
Type:
Application
Filed:
May 20, 2002
Publication date:
January 23, 2003
Inventors:
Joshua D. Rabinowitz, Alejandro C. Zaffaroni
Abstract: This invention discloses benzoxazinone and benzothiazinone compounds which display inhibitory effects on serine proteases such as factor Xa, thrombin, and/or factor VIIa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnornal thrombosis.
Type:
Grant
Filed:
August 14, 2000
Date of Patent:
January 21, 2003
Assignee:
Warner-Lambert Company
Inventors:
Kent Alan Berryman, Dennis Michael Downing, Danette Andrea Dudley, Jeremy John Edmunds, Lakshmi Sourirajan Narasimhan, Stephen Taras Rapundalo
Abstract: Phenothiazine and its derivatives products are provided with a minimal level of fines or dust as a result of forming such products in prill form. The prills are generally spherical. Also provided is a method for reducing the level of powder in phenothiazine product which includes forming the phenothiazine product in prill form such that the prills have a generally spherical shape. The prill product achieves improved handling, flowability and dissolution times, while minimizing the generation of phenothiazine fines and dust, and the problems associated with worker exposure, irritation and sensitization to such fines and dust.
Abstract: The invention concerns novel N-(iminomethyl)amine derivatives comprising in their skeleton the aminophenylamine, oxodiphenylamine, carbazole, phenazine, phenoxazine or oxodiphenyl motif, their use as medicines and pharmaceutical compositions containing them. The invention concerns in particular the following compounds: -4-{[2-thienyl(imino)methyl]amino}-N-[2-(phenylamino)phenyl]-benzenebutanamide; -4-{[2-thienyl(imino)methyl]amino}-N-[4-(phenylamino)phenyl]-benzenebutanamide; -N-′[4-(10H-phenothiazin-2-yloxy)phenyl]-2-thiophenecarboximidamide; -4-(4-{[amino(2-thienyl)methylidene]amino}phenyl)-N-(10H-phenothiazin-3-ylH)butanamide; -3-[(3-{[amino(2-thienyl)methylidene]amino}-benzyl)amino]-N-(4-anilinophenyl)propanamide; -N′-(4-{2-[(10H-phenothiazin-3-ylmethyl)amino]ethyl}phenyl-2-thiophene carboximidamide.
Type:
Grant
Filed:
March 16, 2001
Date of Patent:
November 19, 2002
Assignee:
Societe de Conseils de Recherches et d'Applications
Scientifiques (S.C.R.A.S.)
Abstract: The present invention relates to compounds of the general formula (I)
The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
Type:
Grant
Filed:
October 19, 1999
Date of Patent:
October 22, 2002
Assignees:
Novo Nordisk A/S, Dr. Reddy's Research Foundation
Inventors:
Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
Abstract: A compound of formula (1)
it derivatives, its analogs, its tautomeric forms, its stereoisomers, its polymorphs, its pharmaceutically acceptable salts, or its pharmaceutically acceptable solvates, processes for its preparation and methods of use thereof.
Type:
Grant
Filed:
February 24, 1999
Date of Patent:
August 27, 2002
Assignees:
Dr. Reddy's Research Foundation, Reddy-Cheminor, Inc.
Abstract: The present invention relates to compounds of the general formula (I)
The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).
Type:
Grant
Filed:
October 19, 1999
Date of Patent:
April 2, 2002
Assignees:
Novo Nordisk A/S, Dr. Reddy's Research Foundation
Inventors:
Lone Jeppesen, Paul Stanley Bury, Per Sauerberg
Abstract: The present invention provides a method for eliciting an onset hastened analgesic and anti-inflammatory response and combating nausea in acute migraine attacks. This method comprises administering a pharmaceutical composition comprising more than one active ingredient, wherein said more than one active ingredient consist essentially of:
(i) domperidone or an analogue thereof in an amount sufficient to hasten the onset of the analgesic and anti-inflammatory response and to combat nausea in an acute migraine attack, and
(ii) a NSAID, a pharmaceutically acceptable salt thereof or a pure (−) or pure (+) optical isomeric form thereof in an analgesically and anti-inflammatory effective amount, wherein said NSAID is selected from the group consisting of proprionic acid derivatives, acetic acid derivatives, fenamic acid derivatives, biphenylcarboxylic acid derivatives and oxicams.